Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall
- 1 April 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 29 (Supplement) , N92-N96
- https://doi.org/10.1097/00003246-200104001-00007
Abstract
Staphylococcus aureus is responsible for many nosocomial and community-acquired infections. Its evolving resistance to traditional antimicrobial chemotherapy and emerging prevalence outside of the healthcare environment are serious concerns. This review of the changing epidemiology of methicillin-resistant S. aureus, the emergence of vancomycin (glycopeptide)-resistant isolates, and the mechanisms of resistance to β-lactams and glycopeptides provides an update for clinicians regarding effective strategies for treatment.Keywords
This publication has 40 references indexed in Scilit:
- A Spectrum of Changes Occurs in Peptidoglycan Composition of Glycopeptide-Intermediate Clinical Staphylococcus aureus IsolatesAntimicrobial Agents and Chemotherapy, 2001
- Community‐Acquired Methicillin‐ResistantStaphylococcus aureusin Hospitalized Adults and Children without Known Risk FactorsClinical Infectious Diseases, 1999
- Bacteremia Caused by Staphylococci with Inducible Vancomycin HeteroresistanceClinical Infectious Diseases, 1999
- Methicillin-ResistantStaphylococcus aureusin the Community: A Hospital-Based StudyInfection Control & Hospital Epidemiology, 1999
- Widespread Colonization of Personnel at a Veterans Affairs Medical Center by Methicillin-Resistant, Coagulase-Negative StaphylococcusClinical Infectious Diseases, 1993
- OsteomyelitisDrugs, 1993
- Active Surveillance for Toxic Shock Syndrome in the United States, 1986Clinical Infectious Diseases, 1989
- Resistance of enterococci to antibiotic combinationsJournal of Antimicrobial Chemotherapy, 1986
- Methicillin-resistant staphylococciThe Lancet Healthy Longevity, 1972
- Lysostaphin: Enzymatic mode of actionBiochemical and Biophysical Research Communications, 1965